Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Recommendation of "Moderate Buy" by Analysts

Key Points

• Tarsus Pharmaceuticals has received a consensus recommendation of "Moderate Buy" from analysts, with one hold and five buy ratings reported.
• The average twelve-month price target set by brokerages for Tarsus Pharmaceuticals is $66.67.
• In its latest earnings report, Tarsus missed EPS expectations, reporting ($0.48), while revenue of $102.66 million exceeded estimates.

Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the six ratings firms that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $66.6667.

A number of brokerages have issued reports on TARS. Oppenheimer assumed coverage on Tarsus Pharmaceuticals in a research report on Monday, June 2nd. They set an "outperform" rating and a $75.00 price target for the company. Wall Street Zen cut shares of Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 22nd. HC Wainwright upgraded shares of Tarsus Pharmaceuticals to a "buy" rating and set a $72.00 target price for the company in a research report on Tuesday, May 27th. Finally, The Goldman Sachs Group raised their target price on shares of Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the company a "neutral" rating in a research note on Monday, May 5th.

Tarsus Pharmaceuticals Price Performance

Tarsus Pharmaceuticals stock opened at $58.58 on Friday. The company's 50 day simple moving average is $45.57 and its 200-day simple moving average is $45.99. Tarsus Pharmaceuticals has a 1 year low of $25.82 and a 1 year high of $58.95. The company has a market capitalization of $2.47 billion, a price-to-earnings ratio of -25.14 and a beta of 0.79. The company has a debt-to-equity ratio of 0.22, a quick ratio of 5.21 and a current ratio of 5.26.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.15). Tarsus Pharmaceuticals had a negative return on equity of 32.36% and a negative net margin of 31.13%.The business had revenue of $102.66 million for the quarter, compared to analyst estimates of $95.81 million. As a group, equities research analysts expect that Tarsus Pharmaceuticals will post -3.17 earnings per share for the current year.

Insider Activity at Tarsus Pharmaceuticals

In related news, CEO Bobak R. Azamian sold 6,000 shares of the business's stock in a transaction that occurred on Monday, August 11th. The stock was sold at an average price of $50.00, for a total transaction of $300,000.00. Following the sale, the chief executive officer owned 818,106 shares of the company's stock, valued at $40,905,300. The trade was a 0.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 8.97% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Several hedge funds have recently made changes to their positions in TARS. GF Fund Management CO. LTD. acquired a new stake in Tarsus Pharmaceuticals during the fourth quarter valued at approximately $44,000. Amalgamated Bank lifted its position in shares of Tarsus Pharmaceuticals by 30.1% during the 1st quarter. Amalgamated Bank now owns 1,274 shares of the company's stock valued at $65,000 after acquiring an additional 295 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Tarsus Pharmaceuticals by 26.4% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,623 shares of the company's stock valued at $66,000 after acquiring an additional 339 shares during the last quarter. Quarry LP boosted its stake in shares of Tarsus Pharmaceuticals by 20.0% during the 1st quarter. Quarry LP now owns 3,599 shares of the company's stock worth $185,000 after acquiring an additional 599 shares in the last quarter. Finally, AlphaQuest LLC acquired a new position in shares of Tarsus Pharmaceuticals in the 1st quarter worth $189,000. Institutional investors and hedge funds own 90.01% of the company's stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.